-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Bicara Therapeutics, Maintains $30 Price Target

Benzinga·01/13/2026 13:41:18
Listen to the news
Wedbush analyst David Nierengarten reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and maintains $30 price target.